CARD16
Basic information
Region (hg38): 11:105039092-105101431
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CARD16 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 1 | |||||
missense | 12 | 13 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 4 | |||||
Total | 0 | 0 | 16 | 1 | 1 |
Variants in CARD16
This is a list of pathogenic ClinVar variants found in the CARD16 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
11-105041421-A-C | Benign (Dec 11, 2017) | |||
11-105041422-G-T | not specified | Uncertain significance (Oct 17, 2023) | ||
11-105041443-C-T | not specified | Uncertain significance (Sep 06, 2022) | ||
11-105041506-C-T | not specified | Likely benign (Nov 30, 2021) | ||
11-105041577-C-G | not specified | Uncertain significance (Jun 22, 2023) | ||
11-105041589-A-C | not specified | Uncertain significance (May 05, 2023) | ||
11-105041702-C-G | not specified | Uncertain significance (Oct 26, 2021) | ||
11-105041707-A-G | not specified | Uncertain significance (Nov 08, 2022) | ||
11-105044421-T-C | not specified | Uncertain significance (Jun 30, 2023) | ||
11-105044425-T-C | not specified | Uncertain significance (Jun 30, 2022) | ||
11-105044491-C-T | not specified | Uncertain significance (May 23, 2023) | ||
11-105044496-A-G | not specified | Uncertain significance (Dec 16, 2023) | ||
11-105044505-G-T | not specified | Uncertain significance (Jun 30, 2023) | ||
11-105044524-C-A | not specified | Uncertain significance (Sep 14, 2022) | ||
11-105044532-C-T | not specified | Uncertain significance (Jan 31, 2024) | ||
11-105044551-C-G | not specified | Uncertain significance (Dec 04, 2023) | ||
11-105044557-G-T | not specified | Uncertain significance (Mar 16, 2022) | ||
11-105044619-G-T | not specified | Uncertain significance (Mar 07, 2023) | ||
11-105100546-T-G | not specified | Uncertain significance (Jun 05, 2023) | ||
11-105100564-A-G | not specified | Likely benign (May 17, 2023) | ||
11-105100582-A-G | not specified | Uncertain significance (Apr 08, 2022) | ||
11-105100590-G-A | not specified | Uncertain significance (Oct 26, 2022) | ||
11-105100591-C-A | not specified | Uncertain significance (Jun 03, 2024) | ||
11-105100600-G-A | not specified | Uncertain significance (Mar 07, 2024) | ||
11-105100612-C-T | not specified | Uncertain significance (Dec 20, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CARD16 | protein_coding | protein_coding | ENST00000375706 | 3 | 60106 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.383 | 0.577 | 125715 | 0 | 16 | 125731 | 0.0000636 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.471 | 115 | 102 | 1.13 | 0.00000528 | 1285 |
Missense in Polyphen | 24 | 17.754 | 1.3518 | 258 | ||
Synonymous | -1.50 | 50 | 38.2 | 1.31 | 0.00000201 | 367 |
Loss of Function | 1.62 | 1 | 4.86 | 0.206 | 2.95e-7 | 54 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000738 | 0.000739 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000264 | 0.0000264 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.0000327 | 0.0000327 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Caspase inhibitor. Acts as a regulator of procaspase- 1/CASP1 activation implicated in the regulation of the proteolytic maturation of pro-interleukin-1 beta (IL1B) and its release during inflammation. Inhibits the release of IL1B in response to LPS in monocytes. Also induces NF-kappa-B activation during the pro- inflammatory cytokine response. Also able to inhibit CASP1- mediated neuronal cell death, TNF-alpha, hypoxia-, UV-, and staurosporine-mediated cell death but not ER stress-mediated cell death. Acts by preventing activation of caspases CASP1 and CASP4, possibly by preventing the interaction between CASP1 and RIPK2. {ECO:0000269|PubMed:11432859, ECO:0000269|PubMed:11536016, ECO:0000269|PubMed:16920334}.;
- Pathway
- NOD-like receptor signaling pathway - Homo sapiens (human)
(Consensus)
Intolerance Scores
- loftool
- 0.890
- rvis_EVS
- 0.19
- rvis_percentile_EVS
- 67.03
Haploinsufficiency Scores
- pHI
- hipred
- N
- hipred_score
- 0.330
- ghis
- 0.454
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.0302
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Cop1
- Phenotype
- cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); pigmentation phenotype; neoplasm; homeostasis/metabolism phenotype; growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); endocrine/exocrine gland phenotype;
Gene ontology
- Biological process
- proteolysis;negative regulation of tumor necrosis factor-mediated signaling pathway;negative regulation of lipopolysaccharide-mediated signaling pathway;negative regulation of protein binding;positive regulation of I-kappaB kinase/NF-kappaB signaling;negative regulation of cysteine-type endopeptidase activity involved in apoptotic process;negative regulation of interleukin-1 beta secretion;positive regulation of NF-kappaB transcription factor activity;cellular response to lipopolysaccharide;cellular response to hypoxia;cellular response to UV-C;inhibition of cysteine-type endopeptidase activity
- Cellular component
- protein-containing complex;protease inhibitor complex
- Molecular function
- cysteine-type endopeptidase activity;cysteine-type endopeptidase inhibitor activity;protein binding;kinase binding;identical protein binding;CARD domain binding;caspase binding